The Canals of Hering Might Represent A Target of Methotrexate Hepatic Toxicity

American Journal of Clinical Pathology

Volumn 121, Issue 3, 2004, Pages 324-329

  Hytiroglou, Prodromos ^a   Tobias, Hillel ^c   Saxena, Romil ^b   Abramidou, Martha ^a   Papadimitriou, Constantine S ^a   Theise, Neil D ^c,d  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Canals of Hering; Fibrosis; Liver; Methotrexate; Toxicity

Indexed keywords

CYTOKERATIN 7; METHOTREXATE;

ADULT; AGED; ARTICLE; BILE DUCT INJURY; CANAL OF HERING; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MALE; MULTINUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; SCAR FORMATION; STAINING; STEATOSIS; TISSUE REACTION; TRICHROME STAIN;

EID: 1542287621     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/5HR90TNC4Q4JRXWX     Document Type: Article

References (17)

1. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003:3415-3420.
2. Sausville EA, Longo DL. Principles of cancer treatment. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's PrincipIes of Internal Medicine. Vol 1. 15th ed. New York, NY: McGraw-Hill; 2001:530-547.
3. Dahl MGC, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. Br Med J. 1971;1:625-630.
4. Weinstein G, Roenigk H, Maibach H, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol. 1973;108:36-42.
5. Nyfors A, Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy, 2: findings before and after methotrexate therapy in 88 patients: a blind study. Acta Pathol Microbiol Scand [A]. 1976;84:262-270.
6. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Arch Dermatol. 1989;125:1218-1224.
7. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-716.
8. Nyfors A, Poulsen H. Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis. Am J Surg Pathol. 1977;1:235-243.
9. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate guidelines: revised. J Am Acad Dermatol. 1982;6:145-155.
10. Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RNM, Burt AD, Portmann BC, et al, eds. Pathology of the Liver. 4th ed. London, England: Churchill Livingstone; 2002:621-709.
11. Roenigk HH Jr. Methotrexate and liver biopsies: is it really necessary [editorial]? Arch Intern Med. 1990;150:733-734.
12. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-485.
13. Hopwood D, Nyfors A. Liver ultrastructure in psoriatics related to methotrexate therapy, 2: findings in bile ducts from 11 methotrexate treated psoriatics and 2 controls. Acta Pathol Microbiol Scand [A]. 1977;85:801-811.
14. Theise ND, Saxena R, Portmann BC, et al. The canals of Hering and hepatic stem cells in humans. Hepatology. 1999;30:1425-1433.
15. Saxena R, Hytiroglou P, Thung SN, et al. Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol. 2002;33:983-988.
16. Bjorkman DJ, Hammond EH, Lee RG, et al. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum. 1988;31:1465-1472.
17. Kremer JM, Kaye GI, Kaye NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy: followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum. 1995;38:1194-1203.